Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Immunologic Memory”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

OBJECTIVE: Despite recent advances in neurosurgical resection techniques, radiation therapy, and chemotherapy, malignant gliomas continue to have a dismal prognosis because relapses are unavoidable. METHODS: Dendritic cell vaccination has recently emerged as a promising type of active immunotherapy that aims to induce rather than transfer specific antitumor immune responses in patients. Active immunotherapy is the only type of immunotherapy able to induce immunological memory. RESULTS: Although an increasing number of small clinical trials show safety, feasibility, and immunological and clinical responses, this technology requires further clarification of some critical basic and clinical issues before its presumed place in the treatment of malignant gliomas can be specified. This article addresses the basic and clinical pitfalls that, more than with conventional therapies, may interfere with the potential benefits of this approach. CONCLUSION: Considering the particular mechanisms involved in the immune modulation of tumor biology using dendritic cell-based vaccinations, the authors summarize the arguments in favor of a further, appropriate assessment of this technology.

Brain Neoplasms↗

Effect of heparin on the priming with a protein antigen in mice.

Heparin has been found to stimulate or suppress the priming activity of a protein antigen (cock muscle phosphorylase-b) in mice depending on the various parameters (the dose of antigen, timing of administration, etc.). The adjuvant effect of endotoxin on priming was potentiated by a single dose of heparin injected 10-12 hours after immunization. Optimal doses of heparin incorporated into Freund's incomplete adjuvant also enhanced the humoral immune response first of all the development of 7 S immunologic memory. The possible mechanisms are discussed.

Adjuvants, Immunologic↗

The clinical effectiveness of pneumococcal vaccination: a brief review.

Randomized controlled trials have shown that pneumococcal polysaccharide vaccine is efficacious in preventing pneumococcal bacteraemia and pneumococcal pneumonia in young adults. Clinical trials in older adults, however, have been inconclusive, usually because the studies have been too small. Retrospective studies have shown that pneumococcal vaccination is approximately 50-80% effective in preventing invasive pneumococcal disease among older persons. Vaccination in this age group is also very cost-effective. These findings are the basis for the recent expansion of immunisation policies and the growth in vaccine use in many developed countries. Serologic and clinical studies, however, suggest that vaccine-induced protection declines after 3-5 years, leading to widespread concern about the need for routine revaccination. Because pneumococcal polysaccharide vaccine does not induce immunologic memory, the benefits of revaccination can also be expected to be relatively short-lasting. Alternative strategies of immunological priming of adults with pneumococcal conjugate vaccine followed by boosting with polysaccharide vaccine, or perhaps vaccination with one of the newer protein vaccines, should be considered. Because these new generation pneumococcal vaccines could provide a foundation of life-long protection against pneumococcal infection, their widespread use among adults could have an immense impact on public health worldwide.

Bacterial Vaccines↗

High CD4/CD45RO+ and CD8/CD45RO+ frequencies in children with vaccine-modified measles.

BACKGROUND: Despite availability and wide vaccine coverage, measles infections still occur especially in developing countries. An outbreak of measles occurred among previously immunized older Ghanaian children who had milder clinical symptoms with measles-specific IgG antibodies that could have been attributed to secondary vaccine failure, suggesting that the infection was vaccine-modified measles (VMM). METHODS: Two-color immunophenotyping of the peripheral blood mononuclear cells was performed at acute, recovery and convalescence phases for 19 VMM patients (mean age 6.2 +/- 3.5 years) using flow cytometry, and compared with that of 20 healthy, sex- and age-matched controls. RESULTS: The results showed a significantly higher memory helper (CD4(+)/CD45RO(+)) cell frequency and increased suppressor cell (CD8(+)/CD45R0(+)) frequency in VMM patients compared to healthy controls. There were no complications and all the patients recovered completely. CONCLUSIONS: These findings show that the mild symptoms in patients with VMM may have correlated with the increase of memory T cells, which is in sharp contrast with previous reports on acute measles infection. This may suggest that the intact immunologic memory cells could have been crucial for the resolution of VMM.

Acute Disease↗

Control of idiotope expression by monoclonal anti-idiotope and idiotope-bearing antibody.

Preinjection of C57BL/6 mice with nano-to microgram amounts of a monoclonal IgG1 antibody directed against a binding site-related idiotope of the anti-NP [(4-hydroxy-3-nitro-phenyl)acetyl] antibody B1-8 results in enhancement or suppression of the corresponding and of another B1-8 idiotope in a subsequent anti-NP response, depending on the dose of the injected anti-idiotope antibody. The enhancing and suppressive effects appear two weeks after anti-idiotope administration and are maximal after 6-8 weeks. They are predominantly expressed at the level of IgG, not IgM, antibodies. Enhancement of idiotype expression, i.e. idiotypic memory, can also be induced by the injection of idiotypic antibody of the IgM class, namely antibody B1-8. This effect might represent one of the general mechanisms by which immunological memory is established.

Animals↗

Relationships between 2H4 (CD45RA) and UCHL1 (CD45RO) expression by normal blood CD4+CD8-, CD4-CD8+, CD4-CD8dim+, CD3+CD4-CD8- and CD3-CD4-CD8- lymphocytes.

We characterized and established relationships between the expression of membrane 2H4 (CD45RA) and UCHL1 (CD45RO) by enriched lymphocyte fractions prepared by selective immunomagnetic depletion of monoclonal antibody-defined populations. Cell fractions analysed in this study could be divided into two broad groups according to the presence (CD3+CD4+CD8-, CD3+CD4-CD8+, CD3+CD4-CD8dim+ and CD3+CD4-CD8-) or absence (CD3-CD4-CD8dim+ and CD3-CD4-CD8-) of the CD3 antigen. Preliminary studies confirmed a reciprocal relationship for CD45RA and CD45RO expression by major lymphoid components and further showed that the level or intensity of membrane 2H4 staining (2H4+, 2H4int and 2H4-) could be directly related to UCHL1 expression. As a reflection of their differential functions, the various CD3+ populations examined showed much greater heterogeneity in 2H4 and UCHL1 expression. CD3+CD4+CD8- cells generally showed significant proportions of 2H4+, 2H4int and 2H4- components, whereas the CD3+CD4-CD8+ population was characterized by a predominance of 2H4+ cells. The results of this current investigation further suggested a higher proportion of dual-positive (2H4+UCHL1+) cells and a much greater degree of inter-individual variation than previously suspected. In contrast to CD3+ lymphocytes, natural killer (NK) associated CD3-CD4-CD8dim+ and CD3-CD4-CD8- populations were mostly 2H4+ with only minor 2H4int components and very low expression of UCHL1. An additional observation of note was that the proportions of 2H4+ and 2H4- cells comprising the CD4+CD8- fraction in any given individual was highly correlated (P = 0.002) with the distributions of 2H4+ and 2H4- components within the CD4-CD8+ fraction. This suggests the possible existence of a common control mechanism for the acquisition of immunological memory by distinct lymphocyte populations and further indicates that individual variations in the distribution of 2H4/UCHL1 lymphocyte subpopulations may be a direct consequence of 'immunological experience' rather than age alone.

Antibodies, Monoclonal↗

Immune potential in human uraemia. 2. Changes after regular haemodialysis therapy.

Parameters of both humoral and cellular immune potential were measured in a group of patients with severe renal failure before and after three months' regular haemodialysis therapy. Evidence is presented of improvement in cellular immune potential and of a tendency of the response of lymphocytes to PHA to return to normal. No improvement in humoral responsiveness was demonstrable, and it is suggested that uraemic patients on regular haemodialysis may have an impaired capacity to establish new immunological memory.

Antibodies, Bacterial↗

Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.

BACKGROUND: Experimental gene transfer can make tumors more immunogenic, leading to local regression and inducing immunological memory sufficient to permit resistance to a tumor rechallenge. However, this rarely had any significant impact on large established tumors. METHODS: To analyze potential immunological effects, we used weakly immunogenic pancreatic carcinomas in syngeneic, immunocompetent Lewis rats and performed in situ adenoviral mediated cytosine deaminase (CD) gene transfer followed by administration of the prodrug, 5-fluorocytosine (5FC). In order to reflect the clinical situation, such treated tumors were surgically resected and animals were rechallenged with parental DSL6A pancreatic tumor cells. Tumor growth and cytotoxic activity of immune cells were determined. RESULTS: CD/5FC treatment of the DSL6A cells revealed significant induction of apoptosis in vitro and slowed down tumor progression in syngeneic hosts. Furthermore, we observed neither significant change in tumor growth nor protective immunity in the rechallenged animals. Analysis of T lymphocytes showed no specific cytotoxic activity against DSL6A cells. There was only a trend towards a minor NK cell activation. CONCLUSIONS: Albeit the present study failed to induce protective antitumor immunity, the initial finding of reduced tumor growth argues for the development of multimodal therapeutic options to overcome negative impacts of advanced malignant disease or chemotherapy-related anergy and immunosuppression.

Adenoviridae↗

In vivo state of antiviral CTL precursors. Characterization of a cycling cell population containing CTL precursors in immune mice.

The in vivo state of CD8+ mouse memory CTL specific to lymphocytic choriomeningitis virus (LCMV) was characterized. During acute LCMV infection, the majority of the LCMV-specific CTL activity tested immediately ex vivo was mediated by CD8+ L-selectin- Mac-1+ CTL. The L-selectin- population of CD8+ cells elicited during acute infection also carried > 99% of the restimulatable CD8+ CTL precursors (CTLp) to LCMV, and these required added IL-2 for development into effectors in vitro. In contrast with the acute infection, most of the virus-specific CTLp in immune mice were L-selectin+. Examination of CD8+ T cells in LCMV-immune mice revealed that a L-selectin+ blast-size population of cycling CD8+ cells contained CTLp, which developed into effector CTL in the absence of added IL-2. These cells also expressed Mac-1 and IL-2R. Flow cytometric sorting for IL-2R+ and IL-2R- CD8+ cells in the immune animal revealed, by limiting dilution analysis, similar frequencies of CTLp in both populations. In bulk restimulation assays, the CD25+ CTLp did not require added IL-2 for their in vitro development into effectors, whereas the CD25- CTLp did. Hence, the different requirements for CTLp to effector development in vitro reflect qualitative differences in the in vivo state of the CTLp in the various subpopulations. LCMV-specific memory CTLp that did not require added IL-2 for differentiation were also found in the small-size, noncycling, CD8+L-selectin- cells. In contrast, the small-size, noncycling, CD8+L-selectin+, and CD8+IL-2R- populations also carried CTLp, but these required added IL-2 for development into effector CTL. Hence, T cell memory to LCMV is distributed among various lymphocyte subpopulations in immune animals, and the presence of an activated cycling cell component may account for the long-term perpetuation of antiviral immunologic memory.

Animals↗

Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.

OBJECTIVE: Dendritic cells (DCs) are specialized cells of the immune system that are capable of generating potent immune responses that are active even within the "immunologically privileged" central nervous system. However, immune responses generated by DCs have also been demonstrated to produce clinically significant autoimmunity. Targeting the epidermal growth factor receptor variant III (EGFRvIII), which is a mutation specific to tumor tissue, could eliminate this risk. The purpose of this study was to demonstrate that DC-based immunizations directed solely against this tumor-specific antigen, which is commonly found on tumors that originate within or metastasize to the brain, could be efficacious. METHODS: C3H mice were vaccinated with DCs mixed with a keyhole limpet hemocyanin conjugate of the tumor-specific peptide, PEP-3, which spans the EGFRvIII mutation, or the random-sequence peptide, PEP-1, and were intracerebrally challenged with a syngeneic melanoma expressing a murine homologue of EGFRvIII. RESULTS: Systemic immunization with DCs mixed with PEP-3-keyhole limpet hemocyanin generated antigen-specific immunity. Among mice challenged with intracerebral tumors, this resulted in an approximately 600% increase in the median survival time (>300 d, P < 0.0016), relative to control values. Sixty-three percent of mice treated with DCs mixed with the tumor-specific peptide survived in the long term and 100% survived rechallenge with tumor, indicating that antitumor immunological memory was also induced. CONCLUSION: In a murine melanoma model, immunization with DCs mixed with tumor-specific peptide results in an antigen-specific immunological response that recognizes the EGFRvIII mutation, has potent antitumor efficacy against intracerebral tumors that express EGFRvIII, and results in long-lasting antitumor immunity.

Animals↗

Suppression of memory by passive immunization late in the primary response.

The acquisition of a capacity to respond well to sheep erythrocytes in the presence of anti-SRBC antibody was taken as an indication of the presence of immunological memory. By the use of passive immunization, both the primary IgG plaque-forming cell response and the establishment of memory were abolished, despite occurrence of a full peak IgM PFC response. Evidence for regarding the aquisition of memory and the IgM PFC and IgG PFC responses as three separate processes was presented. Antibody on day 3 of the response to 1.5 x 10(8) SRBC abolished formation of memory; this effect was less if passive immunization was further delayed and absent by day 10.

Animals↗

Idiotype and anti-idiotype specific T cell responses on transplantation with hybridomas reactive to viral hemagglutinin and human tumor antigen.

B cell hybridomas expressing class I and II MHC molecules and producing antibodies directed against hemagglutinin protein of Rinderpest virus and human Mucin-1 have been used as surrogate B cells to study T cell responses against the antigens. The observed CTL and lymphoproliferative response indicates that anti-idiotypic B cells termed Jerne cells stimulate both T helper and T cytotoxic cells by virtue of their ability to present recycled or regurgitated peptido-mimics of antigen to T helper cells through class II MHC and de novo synthesized peptido-mimics of antigens to CTLs. Thus, T cell memory response can be perpetuated by anti-idiotypic Jerne B cells and these findings lend support to the earlier proposed relay hypothesis for perpetuation of immunological memory (IM).

Animals↗

[Immunomodulating action of levamisole in its combined use with influenza vaccines].

The immunomodulatory effect of levamisole used in combination with influenza vaccines was studied in young and senile subjects. Levamisole activated antibody production in young subjects in response to administration of a live influenza A (H3N2) vaccine and enhanced the protective effect of vaccinations. The senile subjects vaccinated with inactivated influenza A vaccine (H3N2 and H1N1) had a good immune response and the use of levamisole was not reflected in antibody rises. At the same time, levamisole alone stimulated antibody production to influenza A and B viruses which might be due to irritation of immunocompetent cells carrying "immunological memory".

Adjuvants, Immunologic↗

Prospects for molecular vaccines in veterinary parasitology.

Despite the profound developments in recombinant DNA technology there is only one marketed recombinant vaccine (for human viral hepatitis B). The development of others proceeds with great difficulty. Molecular vaccines against veterinary parasites are at the utmost pole of complexity in the spectrum of potential vaccines since these parasites are complex eukaryotic organisms, often dwelling at mucosal surfaces where anamnestic responses are problematic, where the immunogenicity of the parasite components is poorly understood and where the effector mechanisms of immunity are unresolved. Cloning a "protective" gene is only the first step, and perhaps the easiest, in a long process which will be necessary to develop vaccines against parasites. Additional steps will involve comprehensive analyses of the immunological responses to ensure that vaccine antigens contain the correct epitopes to induce appropriate immune effector mechanisms for parasite elimination and immunological memory and that these responses are not genetically restricted. The great expectations for recombinant vaccinia-based vaccines must be modified substantially in the light of recent evidence indicating immunological and other constraints on this approach. The use of anti-idiotype vaccines is an underexplored opportunity for practical parasite vaccines since they have several potentially important advantages. The need to include T cell antigenic peptides in peptide vaccines to extend the range of genetic responsiveness and to induce anamnestic responses is now clear. New algorithms for the prediction of such sites exist and these can be tested experimentally with synthetic peptides. There are no major technical obstacles to the development of vaccines for parasites which cannot be overcome. However substantial long term basic research is needed over a range of disciplines to achieve this worthwhile objective.

Animals↗

[Experimental study of the regularity of T-killer induction as a result of anti-rabies immunization].

Experiments in CBA, mice immunized with inactivated unconcentrated cultural rabies vaccine (CRV) demonstrated that a clone of T-effectors of memory was formed within 30-37 days after primary immunization which reacted by the secondary type in response to inoculation of subthreshold doses of the rabies antigen. This clone of immunological memory seems to remain in the quiescent state for very long periods (the observation period 406 days). The immune splenocytes from the donors which had been given subthreshold doses of the antigen at intervals of 60, 103, 180 and 406 days, protected 2-4 times more animals than those after primary immunization with a threshold dose of the antigen. A continuous state of cell-mediated immunity--T-effectors processing the protective properties in vivo--may be maintained by repeated threshold doses of antigen given at 7-day intervals. The observed patterns of the induction of T-effectors possessing protective properties in vivo allowed some principles for construction of the optimal schedule of rabies vaccination to be formulated.

Animals↗

CD8+ T-cell memory in tumor immunology and immunotherapy.

The cellular and molecular mechanisms underlying the formation of distinct central, effector, and exhausted CD8+ T-cell memory subsets were first described in the setting of acute and chronic viral diseases. The role of these T-cell memory subsets are now being illuminated as relevant to the tumor-bearing state. The generation and persistence of productive CD8+ T-cell memory subsets is determined, in part, by antigen clearance, costimulation, responsiveness to homeostatic cytokines, and CD4+ T-helper cells. By contrast, chronic exposure to antigen, negative costimulation, and immunomodulation by CD4+ T regulatory cells corrupt productive CD8+ T memory formation. It has become clear from human and mouse studies that the mere generation of CD8+ T-cell memory is not a 'surrogate marker' for cancer vaccine efficacy. Some current cancer vaccine strategies may fail because they amplify, rather than correct or reset, the corrupted CD8+ memory population. Thus, much of the present effort in the development of vaccines for cancer and chronic infectious diseases is aimed at creating effective memory responses. Therapeutic vaccines for cancer and chronic infectious diseases may achieve consistent efficacy by ablation of the dysfunctional immune state and the provision of newly generated, non-corrupted memory cells by adoptive cell transfer.

Animals↗

'Order from disorder sprung': recognition and regulation in the immune system.

Milton's epic poem Paradise lost supplies a colourful metaphor for the immune system and its responses to pathogens. With the role of Satan played by pathogens seeking to destroy the paradise of human health, GOD intervenes and imposes order out of chaos. In this context, GOD means 'generation of diversity': the capacity of the innate and specific immune responses to recognize and eliminate a universe of pathogens. Thus, the immune system can be thought of as an entity that self-assembles the elements required to combat bodily invasion and injury. In so doing, it brings to bear the power of specific recognition: the ability to distinguish self from non-self, and the threatening from the benign. This ability to define and protect self is evolutionarily very old. Self-recognition and biochemical and barrier defences can be detected in primitive organisms, and elements of these mechanisms are built upon in an orderly way to establish the mammalian immune system. Innate immune responses depend on the use of a limited number of germline-encoded receptors to recognize conserved molecular patterns that occur on the surfaces of a broad range of pathogens. The B and T lymphocytes of the specific immune response use complex gene-rearrangement machinery to generate a diversity of antigen receptors capable of recognizing any pathogen in the universe. Binding to receptors on both innate and specific immune-system cells triggers intricate intracellular signalling pathways that lead to new gene transcription and effector-cell activation. And yet, regulation is imposed on these responses so that Paradise is not lost to the turning of the immune system onto self-tissues, the spectre of autoimmunity. Lymphocyte activation requires multiple signals and intercellular interactions. Mechanisms exist to establish tolerance to self by the selection and elimination of cells recognizing self-antigens. Immune system cell populations are reduced by programmed cell death once the pathogen threat is resolved. Once Paradise has been regained, memory cells remain in the body to sharply reduce the impact of a second exposure to a pathogen. Vaccination programs take advantage of this capacity of the human immune system for immunological memory, sparing millions the suffering associated with disease scourges. Thus does the order of the immune response spring from the disorder of pathogen attacks, and thus is Paradise preserved.

Adaptation, Physiological↗

SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK.

We infected umbilical cord blood lymphocytes (CBL) with EBV in vitro. Analysis of the cell population in 3- and 6-day-old cultures showed a relative increase of B cells and outgrowth of B cells after prolonged culture period. The immunomodulator PSK was added to parallel cultures. In these cultures, B cell growth was inhibited and the activation of T and NK cells was potentiated. This was detected by assessment of SH2D1A (also named SAP or DSHP) expression (a molecule which participates in signal transduction and is mutated in X-linked lymphoproliferative disease, XLP). Upon further cultivation, irradiated autologous EBV infected B cells and IL-2 were added to the cultures. After 17 days, the B lymphocytes were removed from the PSK containing cultures. The remaining populations, containing mainly T and NK cells, exerted cytotoxic function which could act on EBV infected autologous B cells, allogeneic LCL and on K562. Since cellular immunity to EBV is not transmitted to the newborn, EBV specific memory is not involved in the activation of effector cells. Our finding of an in vitro response of T and NK cells to EBV infected B lymphocytes in the absence of EBV specific immunological memory is of particular interest, because it may also operate in vivo and participate in the scenario of primary infection. Its potentiation by immunomodulators may have practical significance.

B-Lymphocytes↗